The recurrence of immunoglobulin A nephropathy (IgAN) after renal transplantation has been described in 40% to 50% of cases. For a long time, this type of recurrence was considered as a benign condition. However, recent data have shown that recurrent IgAN has become a significant cause of long-term allograft loss. The authors present here the case of a 47-year-old man with IgAN, which led to end-stage renal failure in 1999. In November 2000, he received a cadaveric renal allograft. Ten months later, acute nephritic syndrome and rapidly progressive renal failure developed. Renal biopsy showed extracapillary glomerulonephritis with crescent formation in one third of the glomeruli associated with necrosis. Steroid treatment was unsuccessful, and renal function progressively deteriorated with a creatinine level at 3.7 mg/dL 6 months after diagnosis of recurrence. This patient's graft probably will be lost in a few months.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1053/ajkd.2002.36931 | DOI Listing |
Ann Intern Med
January 2025
Renal-Electrolyte Division, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania (M.C.-P., R.B.M., C.M.P.).
Background: Prior studies indicate that 1% to 4% of Epstein-Barr virus (EBV)-seronegative recipients of EBV-seropositive donor (EBV D+/R-) kidneys develop posttransplant lymphoproliferative disorder (PTLD). However, these estimates are based on limited data that lack granularity.
Objective: To determine the associations between pretransplant EBV D+/R- and recipient EBV-seropositive status (R+) and the outcomes of PTLD and graft and patient survival among adult kidney transplant recipients.
Prostate
January 2025
VUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, Detroit, Michigan, USA.
Introduction: PSA screening remains a pivotal tool for early prostate cancer (PCa) detection. International guidelines rely on evidence from three major randomized clinical trials: ERSPC, PLCO, and CAP. We aim to examine the percentage of patients in real-world practice who get PSA screening as defined by each of the aforementioned trials.
View Article and Find Full Text PDFAnnu Rev Med
January 2025
Division of Gastrointestinal and Liver Diseases, Department of Medicine, Keck School of Medicine, University of Southern California, Los Angeles, California, USA; email:
Hepatorenal syndrome-acute kidney injury (HRS-AKI) occurs in the setting of advanced chronic liver disease, portal hypertension, and ascites. HRS-AKI is found in ∼20% of patients presenting to the hospital with AKI, but it may coexist with other causes of AKI and/or with preexisting chronic kidney disease, thereby making the diagnosis challenging. Novel biomarkers such as urinary neutrophil gelatinase-associated lipocalin may be useful.
View Article and Find Full Text PDFAnnu Rev Med
January 2025
SSM Health Saint Louis University Hospital Transplant Center, Saint Louis University, St. Louis, Missouri, USA; email:
Living-donor kidney transplantation is the preferred treatment for kidney failure. In the United States, rates of living kidney donation have been stagnant, which is partly related to concerns over medical and financial risks. Recent research has better characterized the risks of living kidney donation, although the field is limited by a lack of robust registries.
View Article and Find Full Text PDFClin Transplant
February 2025
MEDIC, Research Institute of the McGill University Health Centre, Montreal, Quebec, Canada.
Optimizing the long-term care and follow-up of living kidney donors (LKDs) has been challenging, and prior LKDs have reported suboptimal healthcare experiences. Long-term care of LKDs is largely undertaken by primary care practitioners such as family physicians (FPs). We conducted a cross-sectional survey of Canadian FPs (n = 151).
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!